The care team, not the algorithm, made the difference in heart failure

Published October 27, 2026 · Clinical effectiveness · Cluster-randomized trial · Potentially actionable in supervised care models
Primary source: TIME-HF trial, Circulation, PMID 42668439

The TIME-HF trial enrolled 1,507 adults with heart failure with reduced ejection fraction at 22 centers in India. Centers were randomized to usual care or a nurse-coordinated, mobile-health-supported program incorporating risk stratification, medication and lifestyle optimization, education, outpatient monitoring, and active follow-up. The primary endpoint was days alive and out of hospital over two years.

The modeled probability of surviving the entire 730 days without hospitalization was 46.5% versus 34.7% with usual care—an absolute 11.8-percentage-point difference. There were 163 deaths among 755 intervention participants (21.6%) versus 201 among 752 controls (26.7%), an absolute 5.1-point difference and adjusted mortality hazard ratio 0.78 (95% CI 0.63–0.95). Nearly all participants completed follow-up.

Strength and limitations. Randomization at the center level and two-year clinical endpoints are major strengths. The intervention was multifaceted and cannot identify which component caused the improvement. It was conducted in a predominantly male, often rural population in India; generalizability to U.S. systems, staffing costs, and standard background therapy require evaluation.

Clinical practice: A strong basis for local implementation research around nurse-led follow-up, guideline-directed therapy, access, and adherence—not a mandate to copy the protocol unchanged.